Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials

Title	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials
Authors	Yaqian Xu, Yanping Lin, Yaohui Wang, Liheng Zhou, Shuguang Xu, Yifan Wu, Jing Peng, Jie Zhang, Wenjin Yin, Jinsong Lu
Magazine	EClinicalMedicine
Date	07/17/2021
DOI	10.1016/j.eclinm.2021.101031
Introduction	The study investigates the predictive power of a novel family history scoring system, Neo-Family History Score (NeoFHS), regarding clinical outcomes for breast cancer patients undergoing neoadjuvant platinum-based chemotherapy. Homologous recombination deficiency is linked to sensitivity to platinum-based treatments. However, the significance of family cancer history in this context has been underexplored. This research encompasses 262 patients from SHPD001 and SHPD002 trials, with NeoFHS evaluated based on cancer type, age at diagnosis, kinship, and number of affected relatives. Significant associations were found between NeoFHS and clinical tumour stage, receptor status, and molecular subtype. NeoFHS emerged as an independent predictor of pathological complete response and relapse-free survival, with higher scores correlating with increased chemotherapy-induced adverse events. This biomarker aids in identifying responder candidates and managing treatment safety.
Quote	Yaqian Xu, Yanping Lin and Yaohui Wang et al. Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine. 2021. Vol. 38. DOI: 10.1016/j.eclinm.2021.101031
Materials	Precious Metals
Topics	Biomedical Materials
Industry	Pharmaceutical Industry